1
|
Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, Blanc P, Bouhnik Y, Pariente B, Peyrin-Biroulet L, Boschetti G, Flourié B, Danion P, Savoye G, brazier F, Loreau J, Beaugerie L, Sokol H, Nion-Larmurier I, Bourrier A, Landman C, Lefèvre J, Chafai N, Bouta N, Funakoshi N. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clin Gastroenterol Hepatol 2020; 18:620-627.e1. [PMID: 31202984 DOI: 10.1016/j.cgh.2019.05.060] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Revised: 05/23/2019] [Accepted: 05/29/2019] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS It is a challenge to manage patients with ulcerative proctitis (UP) refractory to standard therapy. We investigated the effectiveness of tumor necrosis factor (TNF) antagonists in a large cohort of patients with refractory UP. METHODS We conducted a nationwide retrospective cohort study of 104 consecutive patients with active UP refractory to conventional therapies, treated at 1 of 15 centers in France or 1 center in Belgium (the GETAID cohort). Patients received at least 1 injection of anti-TNF (infliximab, adalimumab, golimumab) from October 2006 through February 2017. Clinical response was defined as significant improvement in UC-related symptoms, and remission as complete disappearance of UC-related symptoms, each determined by treating physicians. We collected demographic, clinical, and treatment data. The median duration of follow-up was 24 months (interquartile range, 13-51 months). The primary outcome was clinical response of UP to anti-TNF treatment. RESULTS Overall, 80 patients (77%) had a clinical response to anti-TNF therapy and 52 patients (50%) achieved clinical remission. Extra-intestinal manifestations (odds ratio OR, 0.24; 95% CI, 0.08-0.7), ongoing treatment with topical steroids (OR, 0.14; 95% CI, 0.03-0.73), and ongoing treatment with topical 5-aminosalycilates (OR, 0.21; 95% CI, 0.07-0.62) were significantly associated with the absence of clinical remission. Sixty percent (38/63) of the patients who had endoscopic assessment during follow up had mucosal healing. Among the overall population (n = 104), the cumulative probabilities of sustained clinical remission were 87.6% ± 3.4% at 1 year and 74.7% ± 4.8% at 2 years. CONCLUSIONS In a retrospective study of 104 patients with refractory UP, anti-TNF therapy induced clinical remission in 50% and mucosal healing in 60%. About two thirds of the patients were still receiving anti-TNF therapy at 2 years.
Collapse
Affiliation(s)
| | - Aurélien Amiot
- Department of Gastroenterology, Henri Mondor Hospital, Creteil University, Creteil, France
| | - Guillaume Bouguen
- CHU Rennes, Univ Rennes, INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolisms and Cancer), F-35000 Rennes, France
| | - Stéphanie Viennot
- Department of Gastroenterology, University Hospital of Caen, Caen, France
| | - Romain Altwegg
- Department of Gastroenterology, Saint-Eloi Hospital, Montpellier University, Montpellier, France
| | - Edouard Louis
- Department of Gastroenterology, Liège University Hospital, Liège, Belgium
| | - Michael Collins
- Department of Gastroenterology, Bicêtre University Hospital, Le Kremlin-Bicêtre, France
| | - Mathurin Fumery
- Department of Gastroenterology, Amiens University Hospital, Amiens, France
| | - Florian Poullenot
- Department of Gastroenterology, Haut-Leveque Hospital, Bordeaux University, Pessac, France
| | - Laura Armengol
- Department of Gastroenterology, Rouen University Hospital, Rouen, France
| | - Anthony Buisson
- Department of Gastroenterology, Estaing Hospital, Clermont-Ferrand University, Clermont-Ferrand, France
| | - Vered Abitbol
- Department of Gastroenterology, Cochin Hospital, Paris Descartes University, Paris, France
| | - David Laharie
- Department of Gastroenterology, Haut-Leveque Hospital, Bordeaux University, Pessac, France
| | - Philippe Seksik
- Département de Gastroentérologie, Hôpital Saint Antoine, AP-HP, Paris, France
| | - Stéphane Nancey
- Department of Gastroenterology, Lyon-Sud Hospital, Lyon University, Lyon, France
| | - Pierre Blanc
- Department of Gastroenterology, Saint-Eloi Hospital, Montpellier University, Montpellier, France
| | - Yoram Bouhnik
- Department of Gastroenterology, Beaujon Hospital, Paris Diderot University, Clichy, France
| | - Benjamin Pariente
- Department of Gastroenterology, Claude Huriez Hospital, Lille 2 University, Lille, France
| | - Laurent Peyrin-Biroulet
- Department of Gastroenterology, Brabois Hospital, Nancy University, Nancy les Vandoeuvre-lès-Nancy, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Cosnes J, Sokol H, Bourrier A, Nion-Larmurier I, Wisniewski A, Landman C, Marteau P, Beaugerie L, Perez K, Seksik P. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. Aliment Pharmacol Ther 2016; 44:1102-1113. [PMID: 27666569 DOI: 10.1111/apt.13808] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Revised: 07/25/2016] [Accepted: 09/02/2016] [Indexed: 12/21/2022]
Abstract
BACKGROUND The comparative efficacy of adalimumab (ADA) and infliximab (IFX) in Crohn's disease, and the benefit of initial combotherapy with an immunomodulator, are debated. AIM To assess the best anti-TNF treatment regimens in Crohn's disease. METHODS We included 906 biologic-naïve Crohn's disease patients [median age, 31 years (24-41)] and performed a retrospective analysis of 1284 therapeutic exposures to ADA (n = 521) or IFX (n = 763) between 2006 and 2015. An immunomodulator was associated during the first 4-6 months (initial combotherapy) during 706 therapeutic exposures (55%). Median duration of anti-TNF therapy was 39 months (IQR 17-67). Primary outcomes were 6-month and 2-year response rates and drug survival. Logistic regression with propensity scoring and Cox proportional hazard analysis determined variables associated with outcomes. RESULTS The response rates at 6 months and 2 years were 64% and 44% on ADA mono, 86% and 70% on ADA combo, 72% and 45% on IFX mono, and 84% and 68% on IFX combotherapy, respectively. Differences between ADA and IFX were not significant, whereas combotherapy was superior to monotherapy (P < 0.001). Drug survival was longer with combotherapy vs. monotherapy [adjusted hazard ratio 2.17 (1.72-2.70)] and not significantly different between ADA and IFX. During subsequent anti-TNF exposures, IFX combotherapy fared better than other groups regarding response rates, drug survival, disease activity, hospitalisations and abdominal surgery. CONCLUSION In this retrospective analysis of a large tertiary centre cohort of Crohn's disease patients, ADA and IFX had similar efficacy as first line treatment, while initial combotherapy with an immunomodulator improved all outcome measures.
Collapse
Affiliation(s)
- J Cosnes
- Department of Gastroenterology, Saint Antoine Hospital, APHP and Paris VI University, Paris, France.
| | - H Sokol
- Department of Gastroenterology, Saint Antoine Hospital, APHP and Paris VI University, Paris, France
| | - A Bourrier
- Department of Gastroenterology, Saint Antoine Hospital, APHP and Paris VI University, Paris, France
| | - I Nion-Larmurier
- Department of Gastroenterology, Saint Antoine Hospital, APHP and Paris VI University, Paris, France
| | - A Wisniewski
- Department of Gastroenterology, Saint Antoine Hospital, APHP and Paris VI University, Paris, France
| | - C Landman
- Department of Gastroenterology, Saint Antoine Hospital, APHP and Paris VI University, Paris, France
| | - P Marteau
- Department of Gastroenterology, Saint Antoine Hospital, APHP and Paris VI University, Paris, France
| | - L Beaugerie
- Department of Gastroenterology, Saint Antoine Hospital, APHP and Paris VI University, Paris, France
| | - K Perez
- Department of Gastroenterology, Saint Antoine Hospital, APHP and Paris VI University, Paris, France
| | - P Seksik
- Department of Gastroenterology, Saint Antoine Hospital, APHP and Paris VI University, Paris, France
| |
Collapse
|
5
|
Souza JP, Betran AP, Dumont A, de Mucio B, Gibbs Pickens CM, Deneux-Tharaux C, Ortiz-Panozo E, Sullivan E, Ota E, Togoobaatar G, Carroli G, Knight H, Zhang J, Cecatti JG, Vogel JP, Jayaratne K, Leal MC, Gissler M, Morisaki N, Lack N, Oladapo OT, Tunçalp Ö, Lumbiganon P, Mori R, Quintana S, Costa Passos AD, Marcolin AC, Zongo A, Blondel B, Hernández B, Hogue CJ, Prunet C, Landman C, Ochir C, Cuesta C, Pileggi-Castro C, Walker D, Alves D, Abalos E, Moises E, Vieira EM, Duarte G, Perdona G, Gurol-Urganci I, Takahiko K, Moscovici L, Campodonico L, Oliveira-Ciabati L, Laopaiboon M, Danansuriya M, Nakamura-Pereira M, Costa ML, Torloni MR, Kramer MR, Borges P, Olkhanud PB, Pérez-Cuevas R, Agampodi SB, Mittal S, Serruya S, Bataglia V, Li Z, Temmerman M, Gülmezoglu AM. A global reference for caesarean section rates (C-Model): a multicountry cross-sectional study. BJOG 2015; 123:427-36. [PMID: 26259689 PMCID: PMC4873961 DOI: 10.1111/1471-0528.13509] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/27/2015] [Indexed: 12/01/2022]
Abstract
Objective To generate a global reference for caesarean section (CS) rates at health facilities. Design Cross‐sectional study. Setting Health facilities from 43 countries. Population/Sample Thirty eight thousand three hundred and twenty‐four women giving birth from 22 countries for model building and 10 045 875 women giving birth from 43 countries for model testing. Methods We hypothesised that mathematical models could determine the relationship between clinical‐obstetric characteristics and CS. These models generated probabilities of CS that could be compared with the observed CS rates. We devised a three‐step approach to generate the global benchmark of CS rates at health facilities: creation of a multi‐country reference population, building mathematical models, and testing these models. Main outcome measures Area under the ROC curves, diagnostic odds ratio, expected CS rate, observed CS rate. Results According to the different versions of the model, areas under the ROC curves suggested a good discriminatory capacity of C‐Model, with summary estimates ranging from 0.832 to 0.844. The C‐Model was able to generate expected CS rates adjusted for the case‐mix of the obstetric population. We have also prepared an e‐calculator to facilitate use of C‐Model (www.who.int/reproductivehealth/publications/maternal_perinatal_health/c-model/en/). Conclusions This article describes the development of a global reference for CS rates. Based on maternal characteristics, this tool was able to generate an individualised expected CS rate for health facilities or groups of health facilities. With C‐Model, obstetric teams, health system managers, health facilities, health insurance companies, and governments can produce a customised reference CS rate for assessing use (and overuse) of CS. Tweetable abstract The C‐Model provides a customized benchmark for caesarean section rates in health facilities and systems. The C‐Model provides a customized benchmark for caesarean section rates in health facilities and systems.
Collapse
Affiliation(s)
- J P Souza
- Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - A P Betran
- Department of Reproductive Health and Research, UNDP-UNFPA-UNICEF-WHO World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Geneva, Switzerland
| | - A Dumont
- Research Institute for Development, Université Paris Descartes, Sorbonne Paris Cité, UMR 216, Paris, France
| | - B de Mucio
- Latin American Center for Perinatology, Women and Reproductive Health, (CLAP/WR), WHO Regional Office for the Americas, Montevideo, Uruguay
| | - C M Gibbs Pickens
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - C Deneux-Tharaux
- Inserm U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Biostatistics, Paris Descartes University, Paris, France
| | - E Ortiz-Panozo
- Center for Population Health Research, National Institute of Public Health, Cuernavaca, Mexico
| | - E Sullivan
- Faculty of Health, University of Technology, Sydney, NSW, Australia
| | - E Ota
- Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan
| | - G Togoobaatar
- Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan
| | - G Carroli
- Centro Rosarino de Estudios Perinatales, Rosario, Argentina
| | - H Knight
- Royal College of Obstetricians and Gynaecologists, Office for Research and Clinical Audit, Lindsay Stewart R&D Centre, London, UK.,Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
| | - J Zhang
- Ministry of Education-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - J G Cecatti
- Department of Obstetrics and Gynaecology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil
| | - J P Vogel
- Department of Reproductive Health and Research, UNDP-UNFPA-UNICEF-WHO World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Geneva, Switzerland
| | - K Jayaratne
- Family Health Bureau, Ministry of Health, Colombo, Sri Lanka
| | - M C Leal
- Escola Nacional de Saúde Pública (ENSP), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil
| | - M Gissler
- National Institute for Health and Welfare, Helsinki, Finland
| | - N Morisaki
- Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan.,Department of Paediatrics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
| | - N Lack
- Bayerische Arbeitsgemeinschaft für Qualitätssicherung in der Stationären Versorgung (BAQ), Bayerische Krankenhausgesellschaft, Munich, Germany
| | - O T Oladapo
- Department of Reproductive Health and Research, UNDP-UNFPA-UNICEF-WHO World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Geneva, Switzerland
| | - Ö Tunçalp
- Department of Reproductive Health and Research, UNDP-UNFPA-UNICEF-WHO World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Geneva, Switzerland
| | - P Lumbiganon
- Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - R Mori
- Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan
| | - S Quintana
- Department of Gynaecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - A D Costa Passos
- Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - A C Marcolin
- Department of Gynaecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - A Zongo
- Research Institute for Development, Université Paris Descartes, Sorbonne Paris Cité, UMR 216, Paris, France.,Direction de la santé de la famille, Ministère de la Santé, Ouagadougou, Burkina Faso
| | - B Blondel
- Inserm U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Biostatistics, Paris Descartes University, Paris, France
| | - B Hernández
- Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA
| | - C J Hogue
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - C Prunet
- Inserm U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Biostatistics, Paris Descartes University, Paris, France
| | - C Landman
- Escola Nacional de Saúde Pública (ENSP), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil
| | - C Ochir
- School of Public Health, Health Sciences University of Mongolia, Ulaanbaatar, Mongolia
| | - C Cuesta
- Centro Rosarino de Estudios Perinatales, Rosario, Argentina
| | - C Pileggi-Castro
- GLIDE Technical Cooperation and Research, Ribeirão Preto, SP, Brazil.,Department of Paediatrics, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, SP, Brazil
| | - D Walker
- Departments of Obstetrics & Gynaecology and Global Health Sciences, University of California, San Francisco, CA, USA
| | - D Alves
- Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - E Abalos
- Centro Rosarino de Estudios Perinatales, Rosario, Argentina
| | - Ecd Moises
- Department of Gynaecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - E M Vieira
- Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - G Duarte
- Department of Gynaecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - G Perdona
- Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - I Gurol-Urganci
- Royal College of Obstetricians and Gynaecologists, Office for Research and Clinical Audit, Lindsay Stewart R&D Centre, London, UK.,Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
| | - K Takahiko
- Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan
| | - L Moscovici
- Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.,GLIDE Technical Cooperation and Research, Ribeirão Preto, SP, Brazil
| | - L Campodonico
- Centro Rosarino de Estudios Perinatales, Rosario, Argentina
| | - L Oliveira-Ciabati
- Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.,GLIDE Technical Cooperation and Research, Ribeirão Preto, SP, Brazil
| | - M Laopaiboon
- Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen University, Khon Kaen, Thailand
| | - M Danansuriya
- Family Health Bureau, Ministry of Health, Colombo, Sri Lanka
| | - M Nakamura-Pereira
- Escola Nacional de Saúde Pública (ENSP), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil
| | - M L Costa
- Department of Obstetrics and Gynaecology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil
| | - M R Torloni
- Department of Obstetrics, School of Medicine of São Paulo, São Paulo Federal University, São Paulo, Brazil
| | - M R Kramer
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
| | - P Borges
- Escola Nacional de Saúde Pública (ENSP), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil
| | - P B Olkhanud
- School of Public Health, Health Sciences University of Mongolia, Ulaanbaatar, Mongolia
| | - R Pérez-Cuevas
- Social Protection and Health Division, Inter-American Development Bank, Mexico City, Mexico
| | - S B Agampodi
- Family Health Bureau, Ministry of Health, Colombo, Sri Lanka
| | - S Mittal
- Fortis Memorial Research Institute, Gurgaon, Haryana, India
| | - S Serruya
- Latin American Center for Perinatology, Women and Reproductive Health, (CLAP/WR), WHO Regional Office for the Americas, Montevideo, Uruguay
| | - V Bataglia
- Hospital Nacional de Itauguá, Itauguá, Paraguay
| | - Z Li
- Faculty of Health, University of Technology, Sydney, NSW, Australia
| | - M Temmerman
- Department of Reproductive Health and Research, UNDP-UNFPA-UNICEF-WHO World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Geneva, Switzerland
| | - A M Gülmezoglu
- Department of Reproductive Health and Research, UNDP-UNFPA-UNICEF-WHO World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Geneva, Switzerland
| |
Collapse
|